Physician profile
Seth M Gregory
NPI 1649310764
$4,360.82
in general payments reported to CMS, 2019-2025
25 companies · $1,506 in 2025
The $1,506 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $519 · 2020: $247 · 2023: $1,812 · 2024: $277 · 2025: $1,506.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,552 · Travel and Lodging: $1,042.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,552.17 |
| Travel and Lodging | $1,042.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $1,059.48 | 2023 | Da Vinci Surgical System |
| Insmed, INC. | $967.46 | 2023-2025 | Arikayce, Brinsupri |
| Glaxosmithkline, LLC. | $730.44 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals Lp | $293.15 | 2019-2025 | Fasenra, Airsupra, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $240.99 | 2019-2025 | Ofev, Jascayd |
| Actelion Pharmaceuticals US, INC. | $144.98 | 2019-2025 | Opsumit, Uptravi |
| Pulmonx Corporation | $135.76 | 2025 | Zephyr Endobronchial Valve, Chartis Catheter, Pulmonx Chartis Tablet Console |
| United Therapeutics Corporation | $80.71 | 2025 | Tyvaso |
| Grifols USA, LLC | $79.04 | 2019-2023 | Prolastin-C Liquid |
| Regeneron Healthcare Solutions, INC. | $78.45 | 2019-2024 | Dupixent |
| Amgen INC. | $76.13 | 2023-2025 | Tezspire |
| Philips North America LLC | $67.97 | 2019 | |
| Abbvie INC. | $65.03 | 2023-2024 | |
| Genzyme Corporation | $64.60 | 2020-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $57.99 | 2023-2025 | Cuvitru, Glassia |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $48.18 | 2023 | |
| La Jolla Pharmaceutical Company | $39.79 | 2020 | |
| Advanced Respiratory, INC | $20.97 | 2019 | |
| Gilead Sciences, INC. | $17.55 | 2023 | |
| Genentech USA, INC. | $16.63 | 2019 | |
| Optinose US, INC. | $16.32 | 2019 | |
| Circassia INC. | $15.64 | 2020 | |
| Verona Pharma, INC. | $15.62 | 2025 | Ohtuvayre |
| Inspire Medical Systems, INC. | $14.27 | 2025 | Inspire |
| Mylan Specialty L.P. | $13.67 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Seth Gregory listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.